Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06006702
PHASE1

A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

Sponsor: Tyra Biosciences, Inc

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult participants.

Official title: A Phase 1, Multi-cohort, Open-label Study to Evaluate the Relative Bioavailability of Capsule and Tablet Formulations of TYRA-300-B01, and to Evaluate the Safety, Tolerability, and Food Effect of TYRA-300-B01 Tablets in Healthy Adult Participants

Key Details

Gender

All

Age Range

26 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-10-16

Completion Date

2025-07

Last Updated

2025-03-26

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

TYRA-300-B01

TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Locations (1)

Nucleus Network

Melbourne, Victoria, Australia